Customer Contact Center:
1-888-PLMZYME (756-9963)


Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or You may also report side effects to Genentech at 1-888-835-2555.

For further information, please see the Pulmozyme full Prescribing Information.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

Co-Pay Card Program

Pulmozyme Access Solutions Copay Card

Genentech® offers the Pulmozyme Co-Pay Card Program to help you with the out-of-pocket (OOP) costs of your Pulmozyme prescription.

To be eligible, patient must meet the following criteria:

  • Have insurance coverage through commercial insurance (not if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA, DoD, or TRICARE, and where prohibited by law)
  • Have a Pulmozyme co-pay of $30 or more per month

  • Be a Pulmozyme patient of 18 years of age or older, or a legal guardian over the age of 18
  • Cannot be participating in the Genentech® Access to Care Foundation
You pay (for each 30-day prescription)The first $30 of your co-pay AND the remaining cost after your card benefits have been applied
The card covers80% of your co-pay cost after you pay the first $30
The card’s total value isUp to $1,500 per year or $4000 with income verification*

*Once you’ve reached the card’s limit, you will pay your co-pay out-of-pocket for the rest of the year.

Visit, or call 1-877-PZ4URCF (794-8723) for more information and eligibility requirements.

Start using your co-pay card in three easy steps.

Step 1:

To activate the card, call the number or visit the website listed on the front of your card. You will be asked to confirm your residency, annual income, insurance status, card ID, date of birth, last four digits of SSN and contact information.

Step 2:

Present your card along with your prescription to your pharmacist. You only need to show the card the first time.

Step 3:

Afterward, your co-pay assistance will be automatically applied each time you fill your prescription.

You must present your co-pay card to the pharmacist along with your prescription to participate in this program. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Pulmozyme Co-Pay Card Program at 1-877-794-8723 (8AM-8pm EST, Monday-Friday).

When you use your co-pay card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to, Medicare or Medicaid, Medigap, VA or DoD or TRICARE, or where prohibited by law, and you will otherwise comply with the terms above.

We have additional options for
Pulmozyme patients.

Genentech is committed to helping all patients get access to Pulmozyme. Pulmozyme Access Solutions is a free program that can help you find assistance and informational resources available to you.

To speak live with one of our specialists, call 1-800-690-3023 from 6AM to 5PM PT, Monday to Friday; or fax 1-800-963-1792; or visit